Cocrystal Pharma, Inc. (COCP) Stock Price & Analysis

Cocrystal Pharma, Inc. (COCP) rose 0.00% to USD 1.13 as of September 8, 2026 at 08:16 UTC, according to Nexqual real-time market data.

COCP last closed at USD 1.13; the session ranged USD 1.1–1.14 on volume of 43,422 shares. Market capitalization is —, with a 52-week range of USD 0.76–2.67 (NCM). Source: Nexqual, September 8, 2026 at 08:16 UTC.

Key Statistics (as of September 8, 2026 at 08:16 UTC)

Technical Analysis (COCP)

Nexqual's technical model rates COCP "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 08:16 UTC.

From Cocrystal Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• In August 2025 we presented favorable safety and tolerability Phase 1 data from all CDI-988 doses, including the high-dose 1200 mg cohort, at the 2025 Military Health System Research Symposium (MHSRS).   In September 2025 we received a Study May Proceed Letter from the FDA to conduct a Phase 1b challenge study in the U.S. evaluating CDI-988 as a norovirus preventive and treatment.
• In addition, the FDA issued emergency use authorization (EUA) for several antibody and antiviral therapeutics, including and Lagevrio™ (molnupiravir).   We continue pursuing the development of novel antiviral compounds for the treatment of coronavirus infections using our established proprietary drug discovery platform.
• We developed our proprietary structure-based drug design under the guidance of Dr.
• To discover and design these direct-acting antiviral drug candidates, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how.

Partnerships

• As of the date of this Report, it appears that the Company will seek to arbitrate the dispute as required under the agreement with the CRO.
• Aspects of this program were developed in collaboration with Merck, which is legally protecting the intellectual property of the collaboration compounds.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:16 UTC. This page is informational and not investment advice.